There are still lots of open positions. Let's find the one that's right for you.
Arrowhead Pharmaceuticals is seeking experienced and driven Cardiovascular Rare Disease Specialists (RDS) to join our growing commercial team. This is a rare opportunity to play a pivotal role in the commercial launch of Arrowhead's leading investigational cardiometabolic medicine - Plozasiran (siRNA targeting APOC3). This product has demonstrated compelling clinical data to date and is in late-stage development for the treatment of various grievous conditions, including Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Over time, this role could expand to cover additional indications and products in the Arrowhead cardiometabolic portfolio.